Nanomedicine opportunities for cardiovascular disease with perfluorocarbon nanoparticles

Gregory M. Lanza, Patrick M. Winter, Sbelton D. Caruthers, Michael S. Hughes, Tillmann Cyrus, Jon N. Marsh, Anne M. Neubauer, Kathy C. Partlow, Samuel A. Wickline

Research output: Contribution to journalReview article

61 Scopus citations

Abstract

Nanomedicine promises to enhance the ability of clinicians to address some of the serious challenges responsible for cardiovascular mortality, morbidity and numerous societal consequences. Targeted imaging and therapy applications with perfluorocarbon nanoparticles are relevant to a broad spectrum of cardiovascular diseases, ranging from asymptomatic atherosclerotic disease to acute myocardial infarction or stroke. As illustrated in this article, perfluorocarbon nanoparticles offer new tools to recognize and characterize pathology, to identify and segment high-risk patients and to treat chronic and acute disease.

Original languageEnglish
Pages (from-to)321-329
Number of pages9
JournalNanomedicine
Volume1
Issue number3
DOIs
StatePublished - Oct 1 2006

Keywords

  • Atherosclerosis
  • MRI
  • Nanomedicine
  • Nanoparticles
  • Restenosis
  • Stroke
  • Ultrasound

Fingerprint Dive into the research topics of 'Nanomedicine opportunities for cardiovascular disease with perfluorocarbon nanoparticles'. Together they form a unique fingerprint.

  • Cite this

    Lanza, G. M., Winter, P. M., Caruthers, S. D., Hughes, M. S., Cyrus, T., Marsh, J. N., Neubauer, A. M., Partlow, K. C., & Wickline, S. A. (2006). Nanomedicine opportunities for cardiovascular disease with perfluorocarbon nanoparticles. Nanomedicine, 1(3), 321-329. https://doi.org/10.2217/17435889.1.3.321